Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. Tremblay D, et al. Among authors: fleischman a. Leuk Res. 2021 Oct;109:106629. doi: 10.1016/j.leukres.2021.106629. Epub 2021 May 27. Leuk Res. 2021. PMID: 34082375
Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.
Brooks SA, Kim DM, Morse SJ, Nguyen QH, Craver BM, Lai HY, Fleischman AG. Brooks SA, et al. Among authors: fleischman ag. Leuk Res. 2019 Jul;82:11-14. doi: 10.1016/j.leukres.2019.05.003. Epub 2019 May 9. Leuk Res. 2019. PMID: 31128484 Free PMC article. No abstract available.
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O'Connell C, Shammo J, Fleischman AG, Scherber RM, Mesa R, Yacoub A, Perkins C, Meckstroth S, Behlman L, Chiaramonte M, Salehi M, Ziadkhanpour K, Nguyen H, Siwoski O, Hung AK, Janania Martinez M, Nguyen J, Patel S, Kollipara R, Dave A, Randall M, Grant M, Harrison M, Fernandez Soto P, Tremblay D, Hoffman R, Moshier E, Mascarenhas J. Ronner L, et al. Among authors: fleischman ag. Blood. 2020 May 7;135(19):1696-1703. doi: 10.1182/blood.2019003347. Blood. 2020. PMID: 32107559 Free PMC article.
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, Miller CB, Rivera CE, Fleischman AG, Goel S, Heaney ML, O'Connell C, Arcasoy MO, Zhang Y, Kawashima J, Ganz T, Kowalski M, Brachmann CB. Oh ST, et al. Blood Adv. 2020 Sep 22;4(18):4282-4291. doi: 10.1182/bloodadvances.2020002662. Blood Adv. 2020. PMID: 32915978 Free PMC article. Clinical Trial.
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.
Rippel N, Tremblay D, Zubizarreta N, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Kremyanskaya M, Hoffman R, Mesa R, Yacoub A, Mascarenhas J. Rippel N, et al. Among authors: fleischman a. Leuk Res. 2022 Aug;119:106903. doi: 10.1016/j.leukres.2022.106903. Epub 2022 Jun 16. Leuk Res. 2022. PMID: 35717689 Free PMC article.
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera.
Tremblay D, Srisuwananukorn A, Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall A, O'Connell CL, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. Tremblay D, et al. Among authors: fleischman a. Hemasphere. 2022 May 11;6(6):e721. doi: 10.1097/HS9.0000000000000721. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35747843 Free PMC article. No abstract available.
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
Kosiorek HE, Scherber RM, Geyer HL, Verstovsek S, Langlais BT, Mazza GL, Gotlib J, Gupta V, Padrnos LJ, Palmer JM, Fleischman A, Mesa RA, Dueck AC. Kosiorek HE, et al. Among authors: fleischman a. Br J Haematol. 2022 Sep;198(6):1065-1068. doi: 10.1111/bjh.18329. Epub 2022 Jun 24. Br J Haematol. 2022. PMID: 35751150 No abstract available.
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. Maxson JE, et al. Among authors: fleischman ag. N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514. N Engl J Med. 2013. PMID: 23656643 Free PMC article.
340 results